Central nervous system (CNS) disorders affect as many as 1.5 billion people globally. The
limited delivery of most imaging and therapeutic agents into the brain is a major challenge …

In most cases, once nanoparticles (NPs) enter the blood, their surface is covered by
biological molecules, especially proteins, forming a so-called protein corona (PC). As a …

The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain,
hindering treatment of central nervous system (CNS) disorders such as acute ischemic …

Therapies targeting neurological conditions such as Alzheimer's or Parkinson's diseases are
hampered by the presence of the blood-brain barrier (BBB). During the last decades, several …

The blood–brain barrier (BBB) is a tailored system of capillary endothelial cells intermixed
with tight junctions and adherent junctions that regulates the transport of various materials …

Cell-based drug delivery systems have shown tremendous advantages in cancer treatment
due to their distinctive properties. For instance, delivery of therapeutics using tumor-tropic …

A hydroxycinnamic acid derivative, namely ferulic acid (FA) has been successfully
encapsulated in polymeric nanoparticles (NPs) based on poly (lactic-co-glycolic …

Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …

Therapeutic approaches for the delivery of drugs to the central nervous system are
hampered by the presence of the blood–brain barrier (BBB); overcoming this barrier is the …

Brain disorders are a prevalent and rapidly growing problem in the medical field as they
adversely affect the quality of life of a human. With an increase in life expectancy, it has been …